dual agonist glp 1 Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are GLP-1 and Dual GIP/GLP-1 Agonists

You may also want to meet with a registered dietician for diet and meal planning advice

Lower levels of IGF-1 and growth hormone in older adults have been linked with (5, 14): increased fat mass increased cardiovascular risk decreased muscle mass and strength lower cognitive function lower bone density limited joint mobility Several of these traits are seen in frail older adults

( Journal of Orthopaedic Research , 2010) showed that BPC-157 enhanced medial collateral ligament (MCL) healing in rats, with results across multiple routes of administrationintraperitoneal, local application, and even oral

5 : 473476 Chandrasekaran K, Hatanpaa K, Brady DR, Rapoport SI

GIP receptor activation improves how the body processes and stores fat, enhances insulin sensitivity beyond what GLP-1 alone achieves, and appears to reduce the inflammatory signaling associated with excess adipose tissue

10.1016/j.mam.2017.03.005 54